Search | Clinical Trials Finder

The live registry is temporarily unavailable. These stored records may be incomplete or out of date. Check the official record for current status and contact information.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 3:21 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2545–2568 of 4,251 matching trials from the local directory fallback.

Filters: Intervention: Placebo Clear all

Conditions: Kidney Disease, Chronic
Interventions: BI 690517, Empagliflozin, Placebo matching BI 690517; Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 18 Years and older
Enrollment: 8,371 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 53
States / cities: Huntsville, Alabama • Surprise, Arizona • Beverly Hills, California + 46 more

Conditions: Chronic Spontaneous Urticaria
Interventions: Matching placebo, barzolvolimab; Biological
Lead sponsor: Celldex Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 976 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 63
States / cities: Cullman, Alabama • Litchfield Park, Arizona • Scottsdale, Arizona + 47 more

Conditions: Chronic Spontaneous Urticaria
Interventions: Matching placebo, barzolvolimab; Biological
Lead sponsor: Celldex Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 963 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 58
States / cities: Birmingham, Alabama • Fountain Valley, California • Inglewood, California + 50 more

Conditions: Alzheimer Disease
Interventions: Placebo, sabirnetug; Drug
Lead sponsor: Acumen Pharmaceuticals; Industry
Eligibility: 50 Years to 90 Years
Enrollment: 542 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 44
States / cities: Carlsbad, California • Fullerton, California • Irvine, California + 40 more

Conditions: Active Nonsegmental Vitiligo, Stable Nonsegmental Vitiligo
Interventions: Placebo, Ritlecitinib; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 1,571 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 68
States / cities: Scottsdale, Arizona • Bryant, Arkansas • Fountain Valley, California + 47 more

Conditions: Cutaneous Lupus Erythematosus
Interventions: Anifrolumab, Placebo; Combination Product · Other
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 339 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 34
States / cities: Phoenix, Arizona • Covina, California • La Jolla, California + 28 more

Conditions: TBI, Traumatic Brain Injury
Interventions: Placebo, Pregnenolone; Drug
Lead sponsor: Christine Marx, MD; Other
Eligibility: 21 Years to 65 Years
Enrollment: 108 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 2
States / cities: Durham, North Carolina

Conditions: Binge-eating Disorder
Interventions: Placebo, TNX-1900 (Tonix Pharmaceuticals); Drug
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years to 70 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Primary Immune Thrombocytopenia (ITP)
Interventions: Corticosteroids, Ianalumab, Placebo; Drug · Biological
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 100 Years
Enrollment: 226 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2028
U.S. locations: 14
States / cities: Yuma, Arizona • Clovis, California • Fountain Valley, California + 10 more

Conditions: Obesity, Overweight
Interventions: Placebo, Tirzepatide; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 40 Years and older
Enrollment: 15,374 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 165
States / cities: Gilbert, Arizona • Mesa, Arizona • Phoenix, Arizona + 141 more

Conditions: Metabolic Dysfunction-Associated SteatoHepatitis (MASH)
Interventions: ALN-HSD, Placebo; Drug
Lead sponsor: Regeneron Pharmaceuticals; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2028
U.S. locations: 61
States / cities: Flagstaff, Arizona • Peoria, Arizona • Tucson, Arizona + 46 more

Conditions: Colorectal Carcinoma, Colorectal Neoplasm, Lynch Syndrome
Interventions: Adenovirus 5 CEA/MUC1/Brachyury Vaccine Tri-Ad5, Biopsy Procedure, Biospecimen Collection, Colonoscopy, Nogapendekin Alfa, Placebo Administration, Questionnaire Administration; Biological · Procedure · Drug + 1 more
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 186 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2028
U.S. locations: 13
States / cities: Phoenix, Arizona • Tucson, Arizona • San Francisco, California + 10 more

Conditions: Anal Melanoma, Bladder Melanoma, Cervical Melanoma, Esophageal Melanoma, Gallbladder Melanoma, Head and Neck Mucosal Melanoma, Mucosal Melanoma, Nasopharyngeal Mucosal Melanoma, Oral Cavity Mucosal Melanoma, Penile Mucosal Melanoma, Rectal Melanoma, Recurrent Mucosal Melanoma, Sinonasal Mucosal Melanoma, Urethral Melanoma, Urinary System Mucosal Melanoma, Vaginal Melanoma, Vulvar Melanoma
Interventions: Biospecimen Collection, Bone Scan, Cabozantinib S-malate, Computed Tomography, Echocardiography Test, Magnetic Resonance Imaging, Nivolumab, Placebo Administration, Positron Emission Tomography; Procedure · Drug · Biological
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 101 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 142
States / cities: Auburn, California • Berkeley, California • Fremont, California + 116 more

Conditions: Opioid Craving, Opioid Use Disorder, Opioid Withdrawal
Interventions: Hydromorphone, Lofexidine, Naloxone + lofexidine pretreatment, Naloxone + placebo pretreatment; Drug
Lead sponsor: University of Maryland, Baltimore; Other
Eligibility: 18 Years to 65 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2027
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Systemic Lupus Erythematosus
Interventions: Acetaminophen/Paracetamol, Diphenhydramine hydrochloride, Methylprednisolone, Obinutuzumab, Placebo; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 303 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2028
U.S. locations: 14
States / cities: Anniston, Alabama • Searcy, Arkansas • Fullerton, California + 11 more

Conditions: Neurofibromatosis 1, Plexiform Neurofibroma (PN)
Interventions: Placebo, Selumetinib; Other · Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years and older
Enrollment: 145 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2029
U.S. locations: 4
States / cities: Gainesville, Florida • Rockville, Maryland • St Louis, Missouri + 1 more

Conditions: Mild Cognitive Impairment
Interventions: Neurofeedback, Placebo; Behavioral · Other
Lead sponsor: University of California, San Diego; Other
Eligibility: 50 Years to 85 Years
Enrollment: 112 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2026
U.S. locations: 1
States / cities: La Jolla, California

Conditions: Estrogen Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer
Interventions: Giredestrant, Giredestrant-matched Placebo, LHRH Agonist, Letrozole, Letrozole-matched Placebo, Palbociclib; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years and older
Enrollment: 992 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2028
U.S. locations: 38
States / cities: Fountain Valley, California • Long Beach, California • San Leandro, California + 32 more

Conditions: Locally Advanced Pancreatic Adenocarcinoma, Stage III Pancreatic Cancer AJCC v8
Interventions: Biopsy Procedure, Biospecimen Collection, Computed Tomography, Hypofractionated Radiation Therapy, Magnetic Resonance Imaging, Peposertib, Placebo Administration; Procedure · Radiation · Drug + 1 more
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 92 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2027
U.S. locations: 44
States / cities: Duarte, California • Irvine, California • Orange, California + 35 more

Conditions: Chronic Hepatitis B
Interventions: Placebo, TAF; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 2 Years to 17 Years
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2029
U.S. locations: 15
States / cities: Los Angeles, California • San Diego, California • San Francisco, California + 12 more

Conditions: Stage IB Lung Non-Small Cell Carcinoma AJCC v7, Stage II Lung Non-Small Cell Cancer AJCC v7, Stage IIA Lung Cancer AJCC v8, Stage IIB Lung Cancer AJCC v8, Stage IIIA Lung Cancer AJCC v8, Stage IIIA Lung Non-Small Cell Cancer AJCC v7, Stage IIIB Lung Cancer AJCC v8
Interventions: Biospecimen Collection, Carboplatin, Cisplatin, Clinical Observation, Computed Tomography, Crizotinib, Cytology Specimen Collection Procedure, Echocardiography Test, Erlotinib, Gemcitabine Hydrochloride, Nivolumab, Paclitaxel, Pembrolizumab, Pemetrexed, Pemetrexed Disodium, Placebo Administration, Positron Emission Tomography; Procedure · Drug · Other + 1 more
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 7,458 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2027
U.S. locations: 1655
States / cities: Birmingham, Alabama • Daphne, Alabama • Mobile, Alabama + 1013 more

Conditions: Cannabis Use, Marijuana, Psychosis, Schizophrenia, THC
Interventions: Low Dose THC, Placebo, Very Low Dose THC; Drug
Lead sponsor: Yale University; Other
Eligibility: 18 Years to 55 Years
Enrollment: 27 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2028
U.S. locations: 1
States / cities: West Haven, Connecticut

Conditions: Hematopoietic and Lymphoid Cell Neoplasm, Malignant Solid Neoplasm, Sleep Disorder
Interventions: Counseling, Methylphenidate Hydrochloride, Phototherapy, Placebo Administration, Quality-of-Life Assessment, Sham Intervention, Therapeutic Melatonin; Other · Drug · Procedure
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 68 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2028
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Diabetes Mellitus, Type 2, Obesity, Overweight
Interventions: NNC0487-0111, Placebo (matched to NNC0487-0111), Placebo (matched to semaglutide), Semaglutide; Drug
Lead sponsor: Novo Nordisk A/S; Industry
Eligibility: 18 Years and older
Enrollment: 985 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 10
States / cities: Hollywood, Florida • Orange City, Florida • Weston, Florida + 7 more

Search by objective public record fields.

EASi-KIDNEY™ (The Studies of Heart & Kidney Protection With BI 690517 in Combination With Empagliflozin)

A Phase 3 Study of Barzolvolimab in Participants With Chronic Spontaneous Urticaria (CSU)

A Phase 3 Study of Barzolvolimab in Participants With Chronic Spontaneous Urticaria

A Study to Evaluate Efficacy and Safety of Intravenous Sabirnetug in Participants With Early Alzheimer's Disease (ALTITUDE-AD)

A 104-Week Study of Ritlecitinib Oral Capsules in Adults With Nonsegmental Vitiligo (Active and Stable) Tranquillo 2

A Phase III Study to Investigate the Efficacy and Safety of Anifrolumab in Adults With Chronic and/or Subacute Cutaneous Lupus Erythematosus

Novel Intervention for Chronic Complex TBI in OEF/OIF/OND Veterans

A Study of the Effects of Oxytocin in Adults With Binge-eating Disorder

Study of Ianalumab Versus Placebo in Addition to First-line Corticosteroids in Primary Immune Thrombocytopenia (ITP)

A Study of Tirzepatide (LY3298176) on the Reduction on Morbidity and Mortality in Adults With Obesity

A Precision Medicine Approach Using Gene Silencing to Treat a Chronic Liver Disease Called Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Adult Participants at Increased Genetic Risk for This Condition

Testing a Combination of Vaccines for Cancer Prevention in Lynch Syndrome

Using Nivolumab Alone or With Cabozantinib to Prevent Mucosal Melanoma Return After Surgery

Assessing a Clinically-meaningful Opioid Withdrawal Phenotype

A Study to Evaluate the Efficacy and Safety of Obinutuzumab in Participants With Systemic Lupus Erythematosus

Efficacy and Safety of Selumetinib in Adults With NF1 Who Have Symptomatic, Inoperable Plexiform Neurofibromas

Neurofeedback to Improve Working Memory in Mild Cognitive Impairment

A Study Evaluating the Efficacy and Safety of Giredestrant Combined With Palbociclib Compared With Letrozole Combined With Palbociclib in Participants With Estrogen Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer (persevERA Breast Cancer)

Testing the Addition of a New Anti-cancer Drug, M3814 (Peposertib), to the Usual Radiotherapy in Patients With Locally Advanced Pancreatic Cancer

Study of Tenofovir Alafenamide (TAF) in Children and Teen Participants With Chronic Hepatitis B Virus Infection

Genetic Testing in Screening Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been or Will Be Removed by Surgery (The ALCHEMIST Screening Trial)

Probing the Cannabinoid System in Individuals With a Family History of Psychosis

Cognitive Behavioral Therapy and Multimodal Therapy in Treating Sleep Disturbance in Patients With Cancer

AMAZE 8: A Research Study Investigating How Well the Medicine NNC0487-0111 Compared to Semaglutide Helps People With Excess Body Weight and Type 2 Diabetes Lose Weight